论文部分内容阅读
多药耐药性(multidrug resistance,MDRR)是指肿瘤细胞能对多种结构、功能及杀伤机制均不同的化疗药物产生耐受。肿瘤组织多药耐药性的产生主要是由于肿瘤细胞内多药耐药基因的异常扩增和过渡表达所致。目前已分离了两种多药耐药基因:MDR1和MDR3。其中MDR1与肿瘤细胞典型多药耐药有关,目前对MDRl的结构和功能了解较多,它定位于染色体7q21.1,mRNA长度为4.5kb,表达产物是分子量为170KD的糖蛋白(P—glycoprotein,P—GP),又称P1700。该蛋白的作用是作为一种依赖ATP能量的大分子药物或毒物的
Multidrug resistance (MDRR) means that tumor cells can tolerate chemotherapeutic drugs with different structures, functions, and killing mechanisms. The multidrug resistance of tumor tissue is mainly caused by the abnormal amplification and transitional expression of multidrug resistance genes in tumor cells. Two multidrug resistance genes have been isolated: MDR1 and MDR3. Among them, MDR1 is involved in typical multidrug resistance of tumor cells. At present, the structure and function of MDR1 are more well known. It is located on chromosome 7q21.1 and its mRNA is 4.5kb in length. The expression product is a glycoprotein with a molecular weight of 170KD (P-glycoprotein). (P-GP), also known as P1700. The protein acts as a macromolecular drug or poison that depends on ATP energy.